NovaBay Pharmaceuticals has announced that it has received FDA clearance to market its NeutroPhase skin and wound cleanser under widened indications, according to a news release.
The new indications include the moistening and debriding of graft and donor sites. FDA also cleared NeutroPhase to be administered through a new spray pump.
"This new FDA clearance is a major milestone in the recognition of NeutroPhase as an effective wound cleanser and significantly strengthens and enhances its use throughout the surgical community," said Ron Najafi, PhD, CEO and chairman of NovaBay Pharmaceuticals, in the release. "We believe surgeons will be attracted to the flexibility it offers in the grafting and donor arena and its availability in a new easy-to-use spray pump."
NeutroPhase skin and wound cleanser was first cleared in 2007. It is intended for the cleansing and removal of foreign material including microorganisms and debris from wounds and for moistening absorbent wound dressings and cleaning minor cuts, minor burns, superficial abrasions and minor irritations of the skin. It is also intended for moistening and debriding acute and chronic dermal lesions.
NovaBay Pharmaceuticals is headquartered in Emeryville, Calif.
Related Articles on FDA Clearances:
Flexicath Receives FDA Clearance of Pressure Injectable Catheter Series
Hollywog Receives FDA Clearances for Remote Controlled Back Pain Devices
Toshiba Receives FDA Clearance for Vantage Titan 1.5T MRI